Evaluating CVD Medication Adherence Program in Low SES (CVDMAT)
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The investigators propose to evaluate the implementation of a medication adherence program among patients who attend Duke Outpatient Clinic (DOC). It is anticipated that, among the providers' patient panels, at least 100 and up to 300 with CVD risk and poor CVD medication adherence (<0.08 medication possession ratio) will consent to the program.
Using procedures from the investigators previous studies, the investigators will identify potential patients from the EHR, and will identify a pool of potential patients using electronic health records, with the goal of administering the program to at least 100 patients. Patients will be mailed letters, signed by their own provider or medical director of DOC, requesting their participation in the programs. The RA will contact patients via telephone to explain the study, screen for eligibility, and determine what mode of administration individuals prefer to receive the program (SMS, IVR, or email).
The primary outcome will be that the effectiveness/impact of the proposed adherence program will be a 10% improvement in MPR and CVD outcomes (anticipate reducing SBP by 5 mmHg, Hgb a1c by 0.5%, LDL-C by 20 mg/dl).
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
North Carolina
-
Durham, North Carolina, Forenede Stater, 27705
- Duke University Health System Clinic
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Medicaid recipient (preferred); however the investigators will include those patients with other types of insurance or those who are uninsured
- Enrolled in Duke Outpatient Clinic for at least one year
- Outpatient diagnostic code for hypertension and/or hypercholesterolemia and/or diabetes
- Poorly controlled BP levels (>140/90) and/or LDL-C (>130mg/dl) and/or HbA1c of >8 within last 6 months
Exclusion Criteria:
- No access to cell phone
- Not proficient in English
- Nursing home/long-term care facility resident or receiving home health care
- Impaired hearing/ speech/ vision
- Participating in another trial (pharmaceutical or behavioral)
- Planning to leave the area in the next 12 months
- Pregnancy (or planning)
- Diagnosis of life-threatening disease with death probable within 1 year
- Active Diagnosis of psychosis or dementia (has been hospitalized in the last 30 days)
- Diagnosis of ESRD
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: m-health
Patients will receive text message, emails, and monthly phone calls
|
Patients will receive e-reminders via text message and email.
A message library that allows us to disseminate constant and reliable information has been created.
Messages will contain not only medication reminders, but information about issues related to self-management and medication adherence for CVD risk including messages on side-effects, risks/benefits of medication treatment, and barriers to medication adherence.
In addition to these messages, patients will also receive tailored information via telephone by trained research staff.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Adherence to the program's intervention
Tidsramme: 6 months
|
It is measured as the proportion of technology or interventionist contacts responded to by a patient out of those received over the course of the intervention period.
This will be summarized descriptively by type of contact (technology vs. interventionist call) and subdivided by technology (SMS, email).
|
6 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Clinical effectiveness/impact of the program to pill refill adherence
Tidsramme: 6 months
|
This will be measured by pulling pill refill records of those patients who are enrolled.
The investigators anticipate an improvement of 10% on pill refill adherence.
|
6 months
|
|
Clinical effectiveness/impact on BP
Tidsramme: 6 months
|
This will be measured by assessing systolic BP values.
The investigators anticipate reducing SBP by 5 mmHg.
|
6 months
|
|
Clinical effectiveness/impact on A1C
Tidsramme: 6 months
|
This will be measured by assessing A1C values.
The investigators anticipate reducing Hgb A1c by 0.5%.
|
6 months
|
|
Clinical effectiveness/impact on cholesterol
Tidsramme: 6 months
|
This will be measured by assessing LDL-C levels in patients.
The goal is to reduce LDL-C levels by 20 mg/dl.
|
6 months
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Hayden Bosworth, PhD, Duke University
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- Pro00054572
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .